Henry Schein, Inc.

Henry Schein, Inc. (HSIC) Market Cap

Henry Schein, Inc. has a market capitalization of $8.82B.

Price: $77.45

β–² 1.15 (1.51%)

Market Cap: 8.82B

NASDAQ Β· time unavailable

CEO: Andrea Albertini

Sector: Healthcare

Industry: Medical - Distribution

IPO Date: 1995-11-03

Website: https://www.henryschein.com

Henry Schein, Inc. (HSIC) - Company Information

Market Cap: 8.82B|Sector: Healthcare

Company Profile

Henry Schein, Inc. provides health care products and services to dental practitioners and laboratories, physician practices, government, institutional health care clinics, and other alternate care clinics worldwide. It operates through two segments, Health Care Distribution, and Technology and Value-Added Services. The Health Care Distribution segment offers dental products, including infection-control products, handpieces, preventatives, impression materials, composites, anesthetics, teeth, dental implants, gypsum, acrylics, articulators, abrasives, dental chairs, delivery units and lights, X-ray supplies and equipment, personal protective equipment, and high-tech and digital restoration equipment, as well as equipment repair services. This segment also provides medical products comprising branded and generic pharmaceuticals, vaccines, surgical products, diagnostic tests, infection-control products, X-ray products, equipment, and vitamins. The Technology and Value-Added Services segment offers software, technology, and other value-added services that include practice management software systems for dental and medical practitioners. This segment also provides value-added practice solutions, which comprise financial services on a non-recourse basis, e-services, practice technology, network, and hardware services, as well as continuing education services for practitioners, and consulting and other services. Henry Schein, Inc. was founded in 1932 and is headquartered in Melville, New York.

Analyst Sentiment

69%
Buy

From 16 Active Polls

1Y Forecast: $85.43

β–² +10.3% Potential Upside

Consensus Target Metrics

Low Bound

$64

Median

$86

High Bound

$97

Average

$85

Price & Moving Averages

Loading chart...

🎯 Wall Street Analyst Intelligence Report

1-Year structural target targets, chart projections, and sentiment maps.

Average 1Y Target
$85.43
β–² +10.30% Upside
Low Target
$64.00
-17% Risk
Median Target
$86.00
11% Mid
High Target
$97.00
25% Max
Consensus
Hold
14 / 32 Buys

Consensus Trend Projection

Trailing closures vs. 12-month metrics map.

Analyst Vote Distribution

Aggregate institutional coverage sentiment weights.

πŸ“Š Historical Valuation Multiples

Real-time Trailing Twelve Month (TTM) momentum side-by-side with discrete quarterly metrics.

Fiscal QuarterTTMQ1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024
Period EndingTrailing 12MMar 28, 2026Dec 27, 2025Sep 27, 2025Jun 28, 2025Mar 29, 2025Dec 31, 2024Sep 28, 2024Jun 29, 2024
Market Cap ($M)8,8238,2878,9357,9438,9348,4948,6169,2358,191
Enterprise Value ($M)12,43411,89812,46611,24812,14711,59111,36412,10110,891
Price to Earnings Ratio (P/E)22.5419.3622.1219.6625.9719.3022.9123.3219.69
Price/Earnings-to-Growth Ratio (PEG)β€”β€”7.536.4311.43β€”42.7819.25β€”
Price to Sales Ratio (P/S)0.662.462.602.382.762.682.702.912.61
Price to Book Ratio (P/B)2.732.542.752.362.592.572.542.642.33
Price to Free Cash Flow Ratio (P/FCF)20.47-60.9326.4356.33101.52-1415.5954.1978.9333.03
Enterprise Value to Sales (EV/Sales)β€”3.533.633.373.753.663.563.813.47
Enterprise Value to EBITDA (EV/EBITDA)12.5047.7848.6944.1151.6945.8147.9551.2745.76
Debt to Equity Ratio3.631.151.141.020.970.970.850.850.81

⚑ HSIC Growth Runway Model

Standard long term linear growth fade

Multi-Stage Discounted Cash Flow Sandbox

Market Price$77.45
Intrinsic Value$67.12
Market Alignment
Overvalued by 13.3%relative to calculated intrinsic value
9.00%
Exp: 2%2%
i

Growth runway slowdown

This value provides a time window for the growth rate to decline beyond Stage 1 toward the terminal rate. Longer windows are most useful for companies with high growth starting conditions or strong competitive advantages. This option stretches out the growth rate slowdown across 5, 10, or 15-year steps. A high-growth starting condition (exceeding a 25% initial growth rate) automatically applies a curve decay to simulate realistic, rapid market saturation.
i

Terminal growth rate

With long-term inflation between 3-5%, revenue must grow by that baseline to maintain flat real-world market share. This value sets the permanent terminal growth rate to factor into the valuation beyond the growth slowdown runway toward maturity.

3-Stage Financial Runway Horizon

🧠 Perpetuity Horizon Engine (Stage 3: Post-2035)

Terminal FCF Base$0.79B
Perpetuity TV Value$14.84B
Discounted TV (PV)$6.27B
TV Weighting %58.5%
⚠️
Financial Model Disclaimer & Risk Disclosure: This interactive scenario simulator is an educational sandbox provided strictly for informational and analytical research purposes. Core historical financial statements and consensus estimates are sourced directly via Financial Modeling Prep (FMP). All downstream outputs are entirely deterministic, hypothetical projections generated by combining automated mathematical formulas (including linear interpolation and Gaussian bell-curve decay models) with user-selected variables and third-party financial data inputs. Users assume all liability for trading decisions executed based on these sandbox calculations.

πŸ“˜ Full Research Report

ℹ️

AI-Generated Research: This report is for informational purposes only.

πŸ“˜ HENRY SCHEIN INC (HSIC) β€” Investment Overview

🧩 Business Model Overview

Henry Schein operates primarily as a focused healthcare distribution and service platform, serving dental and medical practitioners and organizations. The company sources products from manufacturers, manages procurement and logistics, and supplies customers through an extensive delivery network and digital ordering channels. In parallel, it provides practice-oriented software, services, and IT-enabled offerings that support clinical workflows, purchasing, inventory management, and billing-related administrative needs.

This structure creates a β€œproduct + workflow” proposition: purchasing is supported by reliable fulfillment and product availability, while recurring services increase operational integration inside the customer’s practice. Over time, the combined procurement and software stack reduces the practical ability for customers to switch away without cost and disruption.

πŸ’° Revenue Streams & Monetisation Model

Revenue is generated from (1) distribution of dental and medical consumables and equipment, and (2) services and software tied to practice operations. Distribution revenue is largely transactional (volume-driven), while services/software can be more recurring (seat/license and service-type arrangements).

Key margin drivers include:

  • Product mix and contract economics: gross margin varies with categories, purchasing terms, and the blend between consumables, specialty products, and equipment.
  • Operating leverage: scale in procurement and distribution can spread fixed costs across a larger order base.
  • Services attach and renewal rates: practice management and IT-related revenues tend to be less sensitive to day-to-day ordering volumes, supporting steadier profitability.
  • Working-capital discipline: inventory and payables/receivables management influence free cash flow quality in distribution-led models.

🧠 Competitive Advantages & Market Positioning

HSIC’s moat is strongest in switching costs and cost advantages from scale and logistics, reinforced by an integrated ecosystem around customer purchasing and practice operations.

  • High switching costs (workflow integration): customers that rely on HSIC’s ordering systems, fulfillment cadence, and practice support tools face operational friction in changing vendors, catalog formats, ordering workflows, and IT integrations.
  • Scale purchasing and distribution efficiency: procurement volume and supplier relationships support better unit economics and category coverage, improving competitiveness versus smaller distributors.
  • Logistics and service reach: delivery performance, catalog breadth, and service responsiveness matter in healthcare supply chains, especially for time-sensitive clinical operations.

Competitive benchmarking (primary peers):

  • McKesson and Cardinal Health: both are large, broad healthcare distributors with extensive distribution platforms. Their scale can be formidable, but their industry focus is more diversified across channels, including large-acuity and hospital-centric flows.
  • Patterson Companies: a key dental-focused distributor and services provider. The competitive set is most direct where customer mix, dental category breadth, and practice-technology offerings intersect.

HSIC’s differentiation centers on a more concentrated emphasis on dental and practice-oriented solutions, enabling tighter integration between purchasing, service support, and software-enabled workflows compared with more generalist distribution models.

πŸš€ Multi-Year Growth Drivers

Growth over a 5–10 year horizon is supported by healthcare demand trends and the monetization of workflow digitization in outpatient settings:

  • Outpatient and specialty utilization growth: steady demand for dental and preventive care supports long-run product consumption.
  • Clinical practice modernization: digitized practice workflows and IT-supported administration expand the services/software revenue pool.
  • Category expansion and higher-value mixes: growth in specialty dental products, consumables, and certain equipment categories can lift revenue per customer.
  • Market share capture through execution: customers often value service reliability and comprehensive ordering. Strong execution supports retention and incremental penetration.
  • Customer base rationalization: industry consolidation among providers can create opportunities for larger distributors and integrated service platforms to win accounts.

TAM expansion is driven both by demographic-linked demand (especially dental) and by the gradual shift toward higher-attached services and technology that increase revenue durability versus purely transactional distribution.

⚠ Risk Factors to Monitor

  • Pricing and reimbursement pressure on customers: customer economics influence order frequency and mix, affecting distribution volume and gross margin.
  • Vendor and category concentration: supplier terms and product availability can materially affect unit economics and service levels.
  • Working-capital volatility: inventory management and payables/receivables dynamics are central to cash flow in distribution businesses.
  • Regulatory and compliance exposure: healthcare distribution entails heightened compliance requirements (anti-fraud, contracting rules, and regulated handling practices).
  • Technology, cybersecurity, and operational resilience: software-enabled ordering and practice solutions increase the importance of secure systems and uptime.
  • Competitive intensity: large peers with broad footprints and strong pricing power can pressure margins, especially in commoditized product categories.

πŸ“Š Valuation & Market View

The market typically values healthcare distribution and services through a combination of EV/EBITDA and earnings-based multiples, with incremental value attributed to services/software durability via higher-quality earnings and improved cash flow stability. Key valuation drivers usually include:

  • Operating margin sustainability: evidence of gross margin resilience and controlled operating expense growth.
  • Mix shift toward recurring services: higher attach rates and service renewals can support steadier profitability.
  • Free cash flow conversion: working-capital discipline is often a differentiator versus peers.
  • Return on invested capital (ROIC): distribution models reward efficiency and capital discipline.

Because the business blends transactional distribution with services/software, investors generally underwrite both demand durability and the ability to sustain economics through category mix and operational leverage.

πŸ” Investment Takeaway

HSIC’s long-term investment case rests on a structural combination of switching costs from integrated ordering/workflow relationships, scale-driven cost advantages in procurement and logistics, and an ecosystem approach that supports more durable services revenue. While competition from large diversified distributors and other dental-focused players is ongoing, HSIC’s emphasis on dental/practice integration and execution-backed fulfillment tends to reinforce retention and monetization over time.


⚠ AI-generated β€” informational only. Validate using filings before investing.

πŸ“° Market News & Coverage

15 Stories Available

Real-time institutional reporting and market updates for HSIC.

zacks.comβ€’2026-06-04

Why Is Henry Schein (HSIC) Up 4.6% Since Last Earnings Report?

Henry Schein (HSIC) reported earnings 30 days ago. What's next for the stock?

marketbeat.comβ€’2026-05-30

Henry Schein Sees Steady Dental Demand, $125M Profit Lift by 2026

Henry Schein NASDAQ: HSIC executives said the company is on track with its 2026 commitments and value-creation plan, while pointing to continued momentum in the U.S. dental market despite broader concerns about consumer confidence.

zacks.comβ€’2026-05-28

Here's Why Henry Schein (HSIC) is a Strong Momentum Stock

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

zacks.comβ€’2026-05-28

Is This the Right Time to Keep HSIC Stock in Your Portfolio?

Henry Schein is backed by a dental and medical distribution scale, digital dentistry push and acquisitions, but debt and macro headwinds weigh on its outlook.

seekingalpha.comβ€’2026-05-27

Henry Schein, Inc. (HSIC) Presents at Stifel Jaws & Paws Conference 2026 Transcript

Henry Schein, Inc. (HSIC) Presents at Stifel Jaws & Paws Conference 2026 Transcript

zacks.comβ€’2026-05-22

Here's Why Henry Schein (HSIC) is a Strong Value Stock

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

businesswire.comβ€’2026-05-22

Henry Schein Announces the Election of William K. β€œDan” Daniel as Independent Chairman of the Board

MELVILLE, N.Y.--(BUSINESS WIRE)--Henry Schein, Inc. (Nasdaq: HSIC), the world's largest provider of health care solutions to office-based dental and medical practitioners, today announced that its Board of Directors has elected William K. β€œDan” Daniel as Independent Chairman of the Board, effective May 21, 2026. Mr. Daniel succeeds Stanley M. Bergman, who retired from the Board following 44 years as a Director of Henry Schein and was named Chairman Emeritus in recognition of his extraordinary c.

marketbeat.comβ€’2026-05-17

Henry Schein Highlights Dental Momentum, $125M Savings Goal Despite Medical Softness

Henry Schein NASDAQ: HSIC executives said the company is seeing continued momentum in its dental business and remains committed to previously outlined operating improvement targets, while acknowledging softness in medical tied to a weaker respiratory illness season.

gurufocus.comβ€’2026-05-14

Henry Schein One Releases 2026 Catalyst Index, Revealing Clinical Performance as the Primary Driver of Growth

Henry Schein One, the global leader in dental technology, today announced the release of its [url="]2026 Catalyst Index[/url], the fifth edition of its annual

businesswire.comβ€’2026-05-14

Henry Schein One Releases 2026 Catalyst Index, Revealing Clinical Performance as the Primary Driver of Growth

AMERICAN FORK, Utah--(BUSINESS WIRE)--Henry Schein One, the global leader in dental technology, today announced the release of its 2026 Catalyst Index, the fifth edition of its annual benchmarking report analyzing performance across tens of thousands of DSOs, multi-location organizations, and private practices. This year's data points to a clear and urgent shift for the industry: in a slower economy, growth is no longer determined by scale or efficiency alone; it is driven by clinical execution.

seekingalpha.comβ€’2026-05-13

Henry Schein, Inc. (HSIC) Presents at Bank of America Global Healthcare Conference 2026 Transcript

Henry Schein, Inc. (HSIC) Presents at Bank of America Global Healthcare Conference 2026 Transcript

zacks.comβ€’2026-05-06

Here's Why Henry Schein (HSIC) is a Strong Value Stock

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

seekingalpha.comβ€’2026-05-05

Henry Schein, Inc. (HSIC) Q1 2026 Earnings Call Transcript

Henry Schein, Inc. (HSIC) Q1 2026 Earnings Call Transcript

zacks.comβ€’2026-05-05

Compared to Estimates, Henry Schein (HSIC) Q1 Earnings: A Look at Key Metrics

Although the revenue and EPS for Henry Schein (HSIC) give a sense of how its business performed in the quarter ended March 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

zacks.comβ€’2026-05-05

HSIC Q1 Earnings & Revenues Surpass Estimates, Gross Margin Rises

Henry Schein tops Q1 estimates with 14.8% EPS growth and rising margins, as strong segment performance and market share gains drive solid revenue expansion.

πŸ“Š AI Financial Analysis

Powered by StockMarketInfo
Earnings Data: Q Ending 2026-03-28

"HSIC (2026-03-28, Q1) reported revenue of $3.37B and net income of $107M. EPS was $0.93 (diluted $0.92). On a YoY basis, revenue increased +6.3% (from $3.168B in 2025-03-29) while net income decreased slightly by -2.7% (from $110M). QoQ, revenue declined -2.0% (from $3.437B in 2025-12-27) and net income rose +5.9% (from $101M). Profitability was mixed: gross margin expanded to 31.8% vs 29.1% in Q4, and net margin improved to 3.18% vs 2.94% QoQ; however, net margin was slightly below YoY levels (3.47% in Q1 2025), consistent with the modest YoY net income slip. Cash flow weakened materially in the quarter: operating cash flow was -$97M and free cash flow was -$136M, driven primarily by a large working-capital use (change in working capital of -$278M). Despite negative near-term cash generation, balance sheet leverage appears stable for a non-bank: total assets rose to $11.3B (+0.8% QoQ), while total equity was steady at $4.82B (+0.6% QoQ). The company reduced cash (to $138M) and appears to have continued shareholder returns via buybacks (repurchased -$125M); dividends were $0 in the provided data. Total shareholder return is supported by strong momentum: the stock is up +24.55% over 1Y."

Revenue Growth

Positive

Revenue +6.3% YoY, but -2.0% QoQ from Q4, indicating growth with some quarter-to-quarter volatility.

Profitability

Neutral

Net income -2.7% YoY, but operating/net margins improved QoQ (net margin 3.18% vs 2.94%). Gross margin also expanded QoQ (31.8% vs 28.9%).

Cash Flow Quality

Neutral

Operating cash flow was -$97M and free cash flow -$136M in the quarter, mainly due to working-capital outflows (change in working capital -$278M). Buybacks continued.

Leverage & Balance Sheet

Positive

Total assets up to $11.3B (+0.8% QoQ) and equity stable at $4.82B (+0.6% QoQ). Debt is elevated (net debt $3.61B) but appears consistent rather than deteriorating sharply QoQ.

Shareholder Returns

Good

Strong market momentum: +24.55% 1Y. Buybacks of -$125M supported capital returns; dividends were $0 in the dataset.

Analyst Sentiment & Valuation

Positive

Current price ($78.83) vs consensus target ($85.43) implies modest upside (~+8%). High valuation multiples (e.g., P/E ~19) suggest the market is pricing in durable earnings.

Disclaimer:This analysis is AI-generated for informational purposes only. Accuracy is not guaranteed and this does not constitute financial advice.

Fundamentals Overview

Loading fundamentals overview...

Henry Schein delivered steady revenue growth in Q1 2026 ($3.4B, +6.3% YoY) with a notable margin improvement profile. GAAP operating margin fell 12 bps YoY to 5.41%, but non-GAAP operating margin rose 28 bps to 7.53%. Gross margin expanded 25 bps YoY and 86 bps sequentially, with management explicitly linking it to ongoing value creation execution (value pricing, corporate brand mix outperformance, and supplier cost discipline), suggesting early persistence rather than a transient benefit. The quarter also included a meaningful but non-core $11M remeasurement gain from increasing control of S.I.N. 360, with additional integration-related gains expected only in 2H 2026. Headwinds were concentrated in medical respiratory diagnostics tied to a light flu season (15%-20% of medical business), and premium implant weakness/flatness (more visible in the U.S.). Guidance maintains 2026 sales growth of ~3%-5% and non-GAAP EPS of $5.23-$5.37, assuming oil-related cost increases can be mitigated.

AI IconGrowth Catalysts

  • Henry Schein One launches, including next-generation AI clinical workflow demonstrated at Thrive Live (Las Vegas); AI integrated into global practice management suite
  • Value implants momentum: high single-digit value implant growth; S.I.N. 360 controlling interest supports faster-growing value implant portfolio
  • Dentrix Ascend and Dentally cloud growth: Dentally cloud customers +25% YoY; now >13,000 Dentrix Ascend and Dentale subscribers

Business Development

  • Completed controlling interest transaction in S.I.N. 360 (U.S. distributor for S.I.N. Brazil value implant systems) to strengthen U.S. implant portfolio control and enable integration efficiencies
  • Exclusive supplier initiated opportunities supporting U.S. dental equipment growth (traditional + digital imaging categories)

AI IconFinancial Highlights

  • Global sales: $3.4B (+6.3% YoY); 2.5% local currency internal +3.1% FX +0.7% acquisitions
  • GAAP operating margin: 5.41%, down 12 bps YoY; non-GAAP operating margin: 7.53%, up 28 bps YoY
  • Non-GAAP EPS: $1.32 vs $1.15 prior year; GAAP EPS: $0.92 vs $0.88 prior year; FX added ~+$0.03 diluted EPS
  • Gross margin: +25 bps YoY and +86 bps sequentially vs Q4, attributed to value creation initiatives (value pricing), own brand outperformance and mix, plus improved supplier cost discipline
  • S.I.N. 360 remeasurement gain: $11M (~$0.07 EPS); additional reregimen gains not expected until 2H 2026
  • Medical decline driver: light flu season reduced demand for point-of-care diagnostic test products; category ~15%-20% of medical business; excluding this, medical sales growth would be mid-single digits

AI IconCapital Funding

  • Share repurchases: ~1.6M shares at average $77.64 for ~$125M in Q1 2026
  • Remaining authorized/available repurchases: ~$655M at quarter end
  • Operating cash flow: -$97M (seasonal year-end working capital normalization via accounts payable/accrual decreases); expectation that full-year operating cash flow exceeds net income

AI IconStrategy & Ops

  • Value creation initiatives ongoing: outsourced partner appointed to centralize/select back-office functions; benefits expected later in 2026
  • Strategic buyouts of minority partners in specialty products to unlock integration opportunities
  • Indirect procurement savings via leveraging scale advantage
  • Gross profit initiatives: value pricing and enhanced growth of corporate brands
  • Global e-commerce platform rollout (henryschein.com) to U.S. and Canadian lab customers; >80% of U.S. dental e-commerce sales already transacted via henryschein.com; complete U.S. rollout targeted by end of August

AI IconMarket Outlook

  • 2026 guidance (current continuing operations): sales growth ~3%-5% vs 2025
  • 2026 non-GAAP diluted EPS: $5.23-$5.37; assumed non-GAAP effective tax rate ~24%
  • Adjusted EBITDA expected to grow in mid-single digits vs 2025 adjusted EBITDA of $1.1B
  • Benefits from value creation weighted toward 2H 2026; remeasurement gains recognized in 2026 expected to be less than 2025

AI IconRisks & Headwinds

  • Oil-driven pressure: higher merchandise/freight costs noted; guidance assumes mitigation of rising oil costs and includes plans to protect margins (no quantified bps sensitivity provided)
  • Medical demand cyclicality: respiratory illness/flu season weakness reduced point-of-care diagnostic tests; category ~15%-20% of medical business
  • Premium implant softness: premium implant sales described as flat to down in the U.S. (and lower single digits to flat overall), potentially consumer pressure; improved growth expected as year progresses

Q&A: Analyst Interest

  • Gross margin drivers & persistence: Management attributed Q1 gross margin strength to early value-creation benefits (value pricing), faster/dynamic response to pricing environment, strong corporate brand mix, and improved supplier cost competitiveness; they implied benefits are ongoing rather than a one-quarter event while oil is being mitigated.
  • Oil/freight cost mitigation: Management said crude oil impacts freight costs; they avoid relying solely on fuel surcharges and price defaults. They described mitigation plans in guidance but did not give a numeric oil-to-margin rule, instead stating the guidance assumes mitigation up to a β€œtipping point.”
  • Specialty/implants demand cadence: On specialty, management said Q1 results were in line with expectations with timing of customer buys. They emphasized value implant high single-digit growth and expected improved specialty growth through the year. Premium implants were flat-to-down, especially in the U.S., but improved growth is expected as the year progresses.

Sentiment: MIXED

Note: This summary was synthesized by AI from the HSIC Q1 2026 earnings transcript. Financial data is complex; please verify all metrics against official SEC filings before making investment decisions.

πŸ“‹ Official Regulatory 10-K / 10-Q SEC Filings

Direct authenticated documentation links to audited SEC database reports for HSIC.

SEC EDGAR Live Feed
Loading financial data and tables...
πŸ“

SEC Filings (HSIC)

Β© 2026 Stock Market Info β€” Henry Schein, Inc. (HSIC) Financial Profile